Exela Sterile Medicines LLC
USPTO PatentsView assignee record - 5 granted patents across 2 technology areas, recorded in grant years 2021–2024. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61K (Preparations FOR Medical, Dental OR Toiletry Purposes).
The verdict
According to USPTO PatentsView, Exela ranks #46,623 of 49,997 tracked US assignees by granted-patent volume, with 5 patents across 2 technology areas.
- #46,623
- of 49,997 US assignees by volume
- 46th percentile
- by Innovation Score (34.0/100)
- 21.4
- avg claims per patent
USPTO PatentsView assignee plate
Corpus R46623 · US Corporation #46,623 · 5 grants
GRANTS-MICRO · BOTTOM-DECILE · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-DENSE · TYPE-USCORP · SPAN-YRS · BOOK-RICH
- GRANTS-MICRO 5 grants
- BOTTOM-DECILE #46,623/49,997
- PHOTO-FINISH Exagen
- CPC-NARROW A61K · 2 areas
- INNOV-THIN 34.0/100
- CLAIMS-DENSE 21.4 claims/avg
- TYPE-USCORP US Corporation
- SPAN-YRS 2021–2024 · 4y
- BOOK-RICH 9/10 fields
Nearest grant-volume peer: Exagen Inc. (±0 grants)
Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.
How Exela’s 34.0 Innovation Score adds up
The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.
Innovation-score neighbourhood around Exela
Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.
- Qualcomm Incorporated · highest
Qualcomm Incorporated · highest
85 score
- Exela Sterile… · this assignee 34
Exela Sterile… · this assignee
34 score
- 3D Lighting… · lowest 7
3D Lighting… · lowest
7 score
What this shows Exela's Innovation Score is 34.0/100 (46th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.
Does more volume mean deeper claims for Exela?
Each dot is one of Exela’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Exela’s own 21.4 claims/patent is ABOVE the 14.0 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.
Where Exela's grants concentrate
Exela Sterile Medicines LLC is a focused PatentsView assignee: 2 CPC subclasses with 100% of grants classified under A61K (Preparations FOR Medical, Dental OR Toiletry Purposes). Peak complete grant year is 2021 (2 grants) versus a trough of 1 in 2024. By volume, Exela sits between Exagen Inc. and Exoiq GMBH.
Exela's three-year grant acceleration
Exela Sterile Medicines LLC shows 3 grants in 2022–2024 against only 2 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.
Who files at Exela's volume?
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
- Exagen
Exagen Inc.
5 patents
- Exair
Exair Corporation
5 patents
- Exalt Solutions
Exalt Solutions, Inc.
5 patents
- Excelsior
Excelsior Inc.
5 patents
- Exelway
Exelway Inc.
5 patents
- Exhalation Techno…
Exhalation Technology Limited
5 patents
- Exhaustless
Exhaustless, Inc.
5 patents
- Exoiq
Exoiq GMBH
5 patents
- Exela Sterile Med… ◀
Exela Sterile Medicines LLC
5 patents
What this shows Exela holds 5 patents at rank #46,486, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Companies ranked near Exela
By rank, the assignees closest to #46,486 in granted patent volume.
Leaders in A61K (Preparations FOR Medical)
Other assignees with the most granted patents in Exela's primary technology class.
- The Regents of the University of California 1,779 in class
- L'Oreal 1,250 in class
- Novartis AG 988 in class
- The Procter & Gamble Company 985 in class
- The Board of Regents of the University of Texas System 950 in class
- The United States of America, as represented by the Secretary, Department of Health and Human Services 813 in class
- The Trustees of the University of Pennsylvania 768 in class
- Merck Sharp & Dohme LLC 760 in class
Exela's Innovation Score vs. every tracked assignee
Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)
34 46th percentile higher than 46% of 49,997 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Grants by year
Teal-shaded recent years (2020–present) versus the 2021–2019 baseline. Full figures in the table below.
View data table
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2021 | 2 | 40.0% |
| 2022 | 2 | 40.0% |
| 2024 | 1 | 20.0% |
Which technologies does Exela Sterile Medicines LLC patent most?
Top 2 of 2 technology areas
Data Source
USPTO PatentsView, US granted patents 2015–2025
What to do with this data
Exela Sterile Medicines LLC's patent record in context - here's where to go next.
- Exela Sterile Medicines LLC's lead technology class is A61K (Preparations FOR Medical, Dental OR Toiletry Purposes), 100% of its portfolio - see every assignee active in that class. Explore A61K
- Ranked #46,623 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
- Compare Exela Sterile Medicines LLC against Exagen Inc., an assignee filing at a similar volume. Compare portfolios
- Innovation Score of 34.0/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated
Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.